SynthesisFrontiers in medicine2025
Risk factors for adverse maternal and fetal outcomes in SLE patients: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that increases the risk of adverse maternal and fetal outcomes in SLE pregnancies. Identifying potential risk factors can enhance preconception risk assessment for SLE pregnancies, thereby reducing the burden of pregnancy for SLE patients. Objective: The goal of this meta-analysis is to designate the risk factors for unfavorable maternal and fetal outcomes in SLE pregnancies by means of a systematic review of the literature and meta-analysis. Methods: The odds ratios (ORs) and associated 95% confidence intervals (CIs) were estimated using either a fixed-effects model or a random-effects model. The I Results: Eleven papers with 1,790 SLE patients who were pregnant were examined in the meta-analysis out of 2,467 citations that were screened. The meta-analysis's findings indicated that the onset of SLE is associated with an increased risk of preterm birth (OR: 2.85; 95% CI: 2.04, 3.99). Hypertension is associated with an increased risk of composite pregnancy outcomes (OR: 4.56; 95% CI: 2.42, 8.53), preterm birth (OR: 2.20; 95% CI: 1.53, 3.17) and preeclampsia (OR: 10.11; 95% CI: 1.83, 55.89). Renal involvement is associated with an increased risk of composite pregnancy outcomes (OR: 3.09; 95% CI: 1.66, 5.72) and preterm birth (OR: 1.65; 95% CI: 1.22, 2.23). Anti-dsDNA is associated with an increased risk of preterm birth (OR: 1.83; 95% CI: 1.13, 2.92) and pregnancy loss (OR: 2.64; 95% CI: 1.09, 6.40). Drug therapy is associated with a decreased risk of composite pregnancy outcomes (OR: 0.51; 95% CI: 0.31, 0.85), preterm birth (OR: 0.66; 95% CI: 0.48, 0.89) and pregnancy loss (OR: 0.42; 95% CI: 0.21, 0.84). Sensitivity analysis demonstrated how solid our results are. Egger's test revealed no discernible publication bias. Conclusion: The onset of SLE, hypertension, renal involvement, drug therapy, and serological factors have a predictive effect on the occurrence of adverse maternal and fetal outcomes in SLE pregnancies. Strengthening preconception risk assessment for SLE patients plays an important role in reducing pregnancy risks and improving the quality of life during pregnancy. Systematic review registration: https://www.crd.york.ac.uk/prospero/#recordDetails, identifier: CRD42024564190.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.